Anebulo Pharmaceuticals, Inc. (ANEB) Financial Statements (2023 and earlier)

Company Profile

Business Address JFL CAPITAL MANAGEMENT
LAKEWAY, TX 78734
State of Incorp. DE
Fiscal Year End June 30
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

6/30/2023
12/31/2022
MRQ
6/30/2022
6/30/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments16,355,35014,548,47119,985,645
Cash and cash equivalents16,355,35014,548,47119,985,645
Prepaid expense532,9061,030,9601,123,411
Total current assets:16,888,25615,579,43121,109,056
Noncurrent Assets
Other undisclosed assets   544,435
TOTAL ASSETS:16,888,25615,579,43121,653,491
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1,372,401512,531241,633
Accounts payable346,554380,828110,048
Accrued liabilities1,025,847131,703131,585
Total current liabilities:1,372,401512,531241,633
Noncurrent Liabilities
Total liabilities:1,372,401512,531241,633
Equity
Equity, attributable to parent15,515,85515,066,90021,411,858
Common stock25,63423,34523,345
Additional paid in capital67,398,71160,513,25860,032,597
Accumulated deficit(51,908,490)(45,469,703)(38,644,084)
Total equity:15,515,85515,066,90021,411,858
TOTAL LIABILITIES AND EQUITY:16,888,25615,579,43121,653,491

Income Statement (P&L) (USD)

6/30/2023
12/31/2022
TTM
6/30/2022
6/30/2021
Operating expenses(10,630,297)(6,831,174)(3,613,753)
Operating loss:(10,630,297)(6,831,174)(3,613,753)
Nonoperating income (expense)(7,723)5,555(324)
Investment income, nonoperating   1,020
Other nonoperating expense(13,618)(1,777)(1,344)
Interest and debt expense   (11,767)
Loss from continuing operations before equity method investments, income taxes:(10,638,020)(6,825,619)(3,625,844)
Other undisclosed income from continuing operations before income taxes   12,091
Loss from continuing operations:(10,638,020)(6,825,619)(3,613,753)
Loss before gain (loss) on sale of properties:(6,811,068)(6,825,619)(3,613,753)
Net loss:(10,638,020)(6,825,619)(3,613,753)
Other undisclosed net loss attributable to parent   (26,638,801)
Net loss attributable to parent:(10,638,020)(6,825,619)(30,252,554)
Preferred stock dividends and other adjustments   (8,208,393)
Net loss available to common stockholders, diluted:(10,638,020)(6,825,619)(38,460,947)

Comprehensive Income (USD)

6/30/2023
12/31/2022
TTM
6/30/2022
6/30/2021
Net loss:(10,638,020)(6,825,619)(3,613,753)
Comprehensive loss, net of tax, attributable to parent:(10,638,020)(6,825,619)(3,613,753)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: